New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
05:44 EDTCTICCTI announces DSMB recommendation to continue GOG-0212 Phase 3 trial of Opaxio
Cell Therapeutics, or CTI, announced that the Gynecologic Oncology Group, or GOG, informed CTI that an independent Data Safety Monitoring Board, or DSMB, recommended continuation of the GOG-0212 Phase 3 clinical trial of Opaxio as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled approximately 1,000 of the planned 1,100 patients. Enrollment is expected to be completed in 2013. The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's funded cooperative cancer research groups focused on the study of gynecologic malignancies.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:10 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:31 EDTCTICCTI BioPharma to host conference call
Subscribe for More Information
05:18 EDTCTICCTI BioPharma, Servier enter exclusive PIXUVRI license, collaboration agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use